CA2873278C - Method for quantifying immune cells in tumoral tissues and its applications - Google Patents

Method for quantifying immune cells in tumoral tissues and its applications Download PDF

Info

Publication number
CA2873278C
CA2873278C CA2873278A CA2873278A CA2873278C CA 2873278 C CA2873278 C CA 2873278C CA 2873278 A CA2873278 A CA 2873278A CA 2873278 A CA2873278 A CA 2873278A CA 2873278 C CA2873278 C CA 2873278C
Authority
CA
Canada
Prior art keywords
cells
tumour
stained
density
stained cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2873278A
Other languages
English (en)
French (fr)
Other versions
CA2873278A1 (en
Inventor
Jerome Galon
Franck Pages
Bernhard Mlecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Paris filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of CA2873278A1 publication Critical patent/CA2873278A1/en
Application granted granted Critical
Publication of CA2873278C publication Critical patent/CA2873278C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2873278A 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications Active CA2873278C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2012001446 2012-06-14
IBPCT/IB2012/001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (2)

Publication Number Publication Date
CA2873278A1 CA2873278A1 (en) 2013-12-19
CA2873278C true CA2873278C (en) 2021-10-26

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873278A Active CA2873278C (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Country Status (13)

Country Link
US (1) US10317408B2 (enExample)
EP (1) EP2861986B1 (enExample)
JP (1) JP6449765B2 (enExample)
KR (1) KR102179848B1 (enExample)
CN (1) CN104541167B (enExample)
AU (1) AU2013276470B2 (enExample)
BR (1) BR112014031143B8 (enExample)
CA (1) CA2873278C (enExample)
DE (1) DE13731071T1 (enExample)
ES (1) ES2902879T3 (enExample)
IL (1) IL235738B (enExample)
SG (1) SG11201408107RA (enExample)
WO (1) WO2013186374A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3111221T4 (da) 2014-02-24 2022-04-19 Ventana Med Syst Inc Fremgangsmåder, kit og systemer til scoring af immunresponsen mod cancer ved samtidig påvisning af CD3, CD8, CD20 og FOXP3
CA2955156C (en) * 2014-09-03 2024-04-30 Ventana Medical Systems, Inc. Systems and methods for generating fields of view
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
US10632151B2 (en) 2015-01-22 2020-04-28 University Of Massachusetts Cancer immunotherapy
WO2017070585A1 (en) * 2015-10-23 2017-04-27 Novartis Ag Method of scoring a sample comprising tumor tissue
CN109690314B (zh) * 2016-05-09 2022-08-02 法国国家卫生及研究医学协会 患有实体癌症的患者的分类方法
US11315240B2 (en) * 2016-05-18 2022-04-26 Hoffmann-La Roche Inc. System and method of tumor classification
US12158399B2 (en) * 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
JP7356904B2 (ja) * 2016-10-27 2023-10-05 コーニンクレッカ フィリップス エヌ ヴェ １つ又は複数の組織サンプルにおける細胞組成情報を決定する装置
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
ES2965647T3 (es) 2018-01-31 2024-04-16 Ventana Med Syst Inc Procedimientos y sistemas para la evaluación de infiltrado de células inmunitarias en cáncer colorrectal en estadio III
JP7411667B2 (ja) * 2019-02-05 2024-01-11 ヴェンタナ メディカル システムズ， インク． ステージｉｖの結腸直腸がんにおける免疫細胞浸潤の評価のための方法及びシステム
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen
MX2022004501A (es) 2019-11-07 2022-05-06 Oncxerna Therapeutics Inc Clasificacion de microambientes tumorales.
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
WO2022002874A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
JP2024530213A (ja) 2021-08-10 2024-08-16 ルニット・インコーポレイテッド 病理スライド画像に関する情報を出力する方法及び装置
WO2023175366A1 (en) 2022-03-17 2023-09-21 Veracyte Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627183T2 (de) * 1995-11-30 2004-01-29 Chromavision Med Sys Inc Verfahren zur automatischen bildanalyse biologischer proben
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CA2628317C (en) * 2005-12-19 2015-12-08 Ventana Medical Systems, Inc. Automated lean methods in anatomical pathology
WO2010033508A1 (en) 2008-09-16 2010-03-25 Historx, Inc. Reproducible quantification of biomarker expression
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Also Published As

Publication number Publication date
BR112014031143A2 (pt) 2017-08-08
EP2861986A1 (en) 2015-04-22
BR112014031143B8 (pt) 2022-11-22
AU2013276470A1 (en) 2014-11-27
CN104541167A (zh) 2015-04-22
IL235738B (en) 2019-02-28
US10317408B2 (en) 2019-06-11
BR112014031143B1 (pt) 2022-03-03
CA2873278A1 (en) 2013-12-19
DE13731071T1 (de) 2016-08-18
IL235738A0 (en) 2015-01-29
WO2013186374A1 (en) 2013-12-19
KR20150023760A (ko) 2015-03-05
AU2013276470B2 (en) 2018-06-07
KR102179848B1 (ko) 2020-11-17
EP2861986B1 (en) 2021-11-10
ES2902879T3 (es) 2022-03-30
JP6449765B2 (ja) 2019-01-09
US20150153349A1 (en) 2015-06-04
SG11201408107RA (en) 2015-01-29
JP2015525349A (ja) 2015-09-03
CN104541167B (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
US10317408B2 (en) Method for quantifying immune cells in tumoral tissues and its applications
Bilous et al. Current perspectives on HER2 testing: a review of national testing guidelines
KR102502745B1 (ko) 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치
JP6405319B2 (ja) 乳癌予知のための画像分析
Lloyd et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
EP3117259B1 (en) Assessment of staining quality
US20110111435A1 (en) Detecting Cell Surface Markers
JP5866362B2 (ja) 画像解析による固形腫瘍進行の予後検査
US20240310379A1 (en) A method for measuring a prognostic marker in prostate cancer or in breast cancer
Brügmann et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC
Wang et al. Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance
Liu et al. A comparative performance analysis of multispectral and rgb imaging on her2 status evaluation for the prediction of breast cancer prognosis
CN115602313A (zh) 用于疾病疗效与生存预后预测的生物标志物及其用途
Pinder et al. HER2 testing in the UK: further update to
Maresh et al. Development and Application of Tissue Microarrays for Biomarker Studies
Holten-Rossing Digitalization in pathology

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251009

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128